Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01314014 · ClinicalTrials.gov registry record · Phase 2
Imexon for Relapsed Follicular and Aggressive Lymphomas
A Phase 2 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT01314014: Completed Phase 2 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, sponsored by University of Rochester.
NCT01314014 is a Phase 2 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma that has completed, run by University of Rochester. The registered enrollment target is 22 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01314014, a Phase 2 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether Amplimexon (imexon for injection) is effective in the treatment of indolent and aggressive lymphomas that have progressed after treatment with standard therapies.
Primary Outcome
CT, PET, or MRI scans for the assessment of objective tumor responses were performed at baseline, after cycle 2, and every 3 cycles thereafter until disease progression. Standard response criteria from the International Harmonization Project on Lymphoma were used for classification of objective tumor responses. Response was defined as PR (Regression of measuable disease and no new sites) if \>= 50% decrease in sum of the product of the diameters of up to 6 largest dominant masses; no increase in
Conditions Studied
Interventions
- DRUG Imexon
Study Locations (2)
Arizona
- Arizona Cancer Center, University of Arizona - Tucson
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
What the finished NCT01314014 record still lists
NCT01314014 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower).
The record links to 7 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Imexon is the first listed.
NCT01314014 reports a single indexed study location in Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT01314014 about?
NCT01314014 is a clinical study titled "Imexon for Relapsed Follicular and Aggressive Lymphomas". The purpose of this study is to determine whether Amplimexon (imexon for injection) is effective in the treatment of indolent and aggressive lymphomas that have progressed after treatment with standard therapies.
What is the current status of trial NCT01314014?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2011-05. Estimated completion is 2014-08.
What conditions does trial NCT01314014 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma.
What interventions are being tested in trial NCT01314014?
The interventions under investigation include: Imexon (DRUG).
Who is sponsoring clinical trial NCT01314014?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01314014 being conducted?
This trial has 2 study locations across Arizona, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01314014's enrollment target sits among peer trials
22 94th of 114 higher than 20 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
RECRUITING · Phase 2
-
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia